|Bid||0.00 x 900|
|Ask||0.00 x 40000|
|Day's Range||9.82 - 9.84|
|52 Week Range||8.30 - 10.41|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for BIOT
In more signs of trouble in the blank-check merger market, Blade Therapeutics cancelled its planned deal. Meanwhile another startup is preparing for a shareholder vote after offering a disappointing financial forecast.
Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, Calif., today announced that they have mutually agreed to terminate the previously announced Agreement and Plan of Merger (the "Merger Agreement"), effective immediately.
Even as some SPACs get tripped up, Senti plans to use its merger to push two cell therapies into clinical trials, sign more deals with gene therapy companies and open a manufacturing center in Alameda.